论文部分内容阅读
系统性红斑狼疮(SLE)是一种自身免疫介导的弥漫性结缔组织病,是继发性的抗磷脂综合征(APS)的典型代表。抗β2糖蛋白I(β2-GPI)抗体是APS的一种主要抗体,是沟通免疫和凝血两大生理系统的桥梁之一。但β2-GPI抗体阳性的SLE患者中,只有部分发生血栓/栓塞。人群中抗β2-GPI抗体不仅可分为不同的亚型,更存在不同的亚群,可识别抗原不同的功能区,并与血栓事件之间存在不同的关联性。该文就β2-GPI抗体的研究进展予以综述。
Systemic lupus erythematosus (SLE) is an autoimmune-mediated diffuse connective tissue disease and is a classic example of secondary antiphospholipid syndrome (APS). Anti-β2-glycoprotein I (β2-GPI) antibody is a major antibody to APS and is one of the bridges that bridge the two physiological systems of immunity and coagulation. However, only partial thrombosis / embolism occurs in patients with β2-GPI-positive SLE. Anti-β2-GPI antibodies in human population can not only be divided into different subtypes, but also exist in different subgroups, which can recognize different functional domains of antigens and have different correlations with thrombosis events. This article reviews the research progress of β2-GPI antibody.